FibroGen Inc (FGEN) concluded trading on Thursday at a closing price of $0.77, with 121.48 million shares of worth about $93.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 104.50% during that period and on February 20, 2025 the price saw a gain of about 37.44%. Currently the company’s common shares owned by public are about 100.77M shares, out of which, 94.10M shares are available for trading.
Stock saw a price change of 69.39% in past 5 days and over the past one month there was a price change of 45.71%. Year-to-date (YTD), FGEN shares are showing a performance of 45.87% which decreased to -64.73% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.18 but also hit the highest price of $2.80 during that period. The average intraday trading volume for FibroGen Inc shares is 1.13 million. The stock is currently trading 49.50% above its 20-day simple moving average (SMA20), while that difference is up 54.73% for SMA50 and it goes to 22.81% higher than SMA200.
FibroGen Inc (NASDAQ: FGEN) currently have 100.77M outstanding shares and institutions hold larger chunk of about 36.16% of that.
The stock has a current market capitalization of $77.83M and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$1.23 in the same period. It has Quick Ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FGEN, volatility over the week remained 16.90% while standing at 10.94% over the month.
Analysts are in expectations that FibroGen Inc (FGEN) stock would likely to be making an EPS of -0.2 in the current quarter, while forecast for next quarter EPS is -0.1 and it is -0.38 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.2 which is -0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.57 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 72.60% while it is estimated to increase by 43.12% in next year. EPS is likely to grow at an annualized rate of 49.32% for next 5-years, compared to annual growth of -23.23% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on August 08, 2023 offering an Underperform rating for the stock and assigned a target price range of between $4 and $2 to it. Stock get a Neutral rating from BofA Securities on June 26, 2023.
